Skip to main content

Macugen FDA Approval History

FDA Approved: Yes (Discontinued) (First approved December 17, 2004)
Brand name: Macugen
Generic name: pegaptanib
Dosage form: Ophthalmic Injection
Company: Eyetech / Pfizer Inc
Treatment for: Macular Degeneration

Macugen (pegaptanib) is a selective vascular endothelial growth factor (VEGF) antagonist indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

Development timeline for Macugen

Dec 17, 2004Approval Macugen Eyetech / Pfizer Inc - Treatment for Neovascular (Wet) Age-Related Macular Degeneration
Aug 27, 2004FDA Advisory Committee Reviews Clinical Data of Eyetech/Pfizer Priority 1 NDA Submission for Macugen, an Investigational Treatment for Neovascular AMD
Aug 18, 2004Eyetech/Pfizer Announce FDA Acceptance of the New Drug Application for Macugen (pegaptanib sodium injection)
Jun 17, 2004Eyetech/Pfizer File New Drug Application for Macugen (pegaptanib sodium injection), the First Investigational Anti-VEGF Therapy for Wet Age-Related Macular Degeneration
May 26, 2004FDA Announces Advisory Committee Meeting Date for Macugen (pegaptanib sodium injection)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.